Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance

BACKGROUND: Tyrosine kinase inhibitor (TKI) treatment has significantly improved the prognosis of oncogenic-driven lung adenocarcinoma (LUAD). However, drug resistance limits the long-term benefits of patients. Therefore, there is a pressing need to explore the mechanism of TKI resistance and identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chuanfen, Wang, Chunmei, Yang, Zhenyu, Bai, Yuquan, Shukuya, Takehito, Poh, Mau-Ern, Ekman, Simon, Li, Jian, Xu, Yuyang, Deng, Senyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186177/
https://www.ncbi.nlm.nih.gov/pubmed/35693278
http://dx.doi.org/10.21037/tlcr-22-318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186177/
https://www.ncbi.nlm.nih.gov/pubmed/35693278
http://dx.doi.org/10.21037/tlcr-22-318

Ejemplares similares